Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of a combined COVID-19 recombinant spike vaccine and high-dose influenza vaccine in adults aged 60 years and older
2026-526221-18-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of NVX-CoV2373, influenza vaccine (quadrivalent, high-dose) and Fluzone High-Dose + Nuvaxovid in influenza and coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Sanofi. Primary endpoints: Antibody titers against each of the 3 influenza vaccine strains and Antibody titers against SARS-CoV-2 specific variant. Planned start Oct 2026; status: authorised.
02
Drugs
NVX-CoV2373influenza vaccine (quadrivalent, high-dose)Fluzone High-Dose + Nuvaxovid
03
Conditions
influenzacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2026-526221-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526221-18-00.